WEDNESDAY, JULY 02, 2025
Nagaland Districts
Published on Jan 24, 2021
By EMN
Share
Dimapur, Jan. 23 (EMN): Nagaland recorded 33 new Covid-19 cases and zero deaths in the week ending January 22, according to an update by the department of Health and Family Welfare.
It said a total of 34,450 contacts have been traced by surveillance teams so far and the most-affected age group is 21-30 years at 26%, followed by 31-40 years at 25%.
“The uncontrolled spread among the age group of 21-40 years is increasing risk in the higher age groups,” it stated, adding that ‘29% positivity rate among household contacts continue to remain, followed by government employees at 23% and students at 19%’.
“The positivity rate among symptomatic/ pre-op screening/ travel purposes coming to Flu clinics continues to remain high at 15% (745/4997) which is worrisome,” it added.
4480 healthcare workers vaccinated
A total of 4480 healthcare workers (doctors, nurses and support staff) from across 11 districts received Covidshield in the first week of Covid-19 vaccination drive and no adverse events which needed medical management were reported, informed Health department in an update.
The district-wise break-up of people who have been vaccinated is: Kohima-823, Dimapur-784, Mokokchung- 655, Zunheboto-435, Mon-418, Phek-375, Wokha-367, Peren-255, Tuensang-180, Longleng-114, and Kiphire-74.
Covid-19 vaccination is carried in the state on Monday, Tuesday and Wednesday.
The department informed that so far, more than 10 lakh healthcare workers in India had received either Covishield, manufactured by Serum Institute of India and developed by the Oxford University and AstraZeneca, or Covaxin, produced by Bharat Biotech in collaboration with ICMR.
It went on to inform that Covishield has more than 70% efficacy, while Covaxin’s initial clinical trials had shown good immunogenicity and “proven to be very safe”.
“Vaccination offers the safest way to cut short the pandemic and reduce mortality. The need for vaccination is more urgently felt in the threat of emergence of many SARS COV 2 Variants as more transmission will lead to emergence of more variants which are poorly understood,” the update read.
As for adverse events following immunisation, it said a small fraction of the beneficiaries will experience mild fever, pain at injection site, body ache, lethargy, head ache etc. which will subside in a day or two or with medicines like paracetamol. These symptoms are just the body reacting to the vaccine and is normal, as is seen in routine immunisation of children, it said.